drugset / Trial / NCT03021876

L-carnitine Corrects Ammonia Metabolism in Hepatectomized Patients

NCT03021876

Phase 2/3 Unknown 80 enrolled Kochi University
RandomizedParallel-groupOpen-labelTreatment

Summary

L-carnitine is synthesized from lysine and methionine. Postmortem concentrations of carnitine in liver, muscle, heart, kidney, and brain averaged only one-fourth to one-third those in corresponding tissues of eight normally nourished non-hepatic patients who died after an acute illness of a 1-3-day duration. In the recent years, it has been reported that sirtuin 3 (SIRT3) is protective against acute kidney injury (AKI) and suggest that enhancing SIRT3 to improve mitochondrial dynamics has potential as a strategy for improving outcomes of renal injury. In the current study, it is the first clinical interventional research whether L-carnitine corrects ammonia metabolism associated with liver injury in hepatectomized patients.

Timeline

Start
2016-04
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator L-carnitine Other / unclassified 1500 mg Oral

Indications

No indication recorded.